Introduction to anifrolumab and its marketing status

Anifrolumab, brand name Saphnelo, is a new treatment for systemic lupus erythematosus (SLE). This drug is primarily used to treat people with moderate to severe systemic lupus erythematosus, especially if they are receiving other standard therapies. As a monoclonal antibody, anilumab works by targeting and blocking type I interferon (INF-1) receptors and belongs to the interferon antagonist class of drugs. This mechanism enables anilumab to effectively reduce immune and inflammatory responses, thereby helping to improve the symptoms of SLE patients.

Systemic lupus erythematosus is a common autoimmune disease in which patients have an abnormally active immune system that attacks their own healthy tissues, causing pain and inflammation in various parts of the body. Research shows that the level of type I interferon in patients with SLE is usually too high. This excess interferon signal can trigger a series of unnecessary inflammatory reactions and further aggravate the progression of the disease. Anilumab is designed to address this problem. Its mechanism of action works by blocking the INF-1 receptor, thereby reducing inflammatory signals in the immune system, helping to improve patients' clinical manifestations and reduce the frequency of lupus attacks.

On July 30, 2021, anilumab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severe SLE. The approval was based on the positive results of the TULIP-2 Phase III clinical trial. It should also be noted that anilumab is not suitable for the treatment of severe active lupus nephritis or severe active central nervous system lupus, and is not recommended for patients under the age of 18.

Overall, anilumab represents a new advance in the treatment of systemic lupus erythematosus, providing a new biological treatment option and bringing new hope to patients who cannot obtain satisfactory results from traditional treatments. With the accumulation of more clinical data and further research on the long-term efficacy and safety of this drug, anilumab is expected to play a more important role in the future treatment of SLE.

Currently, anilumab is not on the market in China, and patients are temporarily unable to purchase the drug directly in domestic hospitals. It is understood that anilumab is on the market in Europe, with a specification of 300mg and a price of about 17,000 yuan. If the patient needs the medication of anilumab, he or she can consult with Yaode’s overseas medical consultant for more information.

Reference link: https://www.drugs.com/anifrolumab.html